GB202306028D0 - Prostate cancer - Google Patents

Prostate cancer

Info

Publication number
GB202306028D0
GB202306028D0 GBGB2306028.8A GB202306028A GB202306028D0 GB 202306028 D0 GB202306028 D0 GB 202306028D0 GB 202306028 A GB202306028 A GB 202306028A GB 202306028 D0 GB202306028 D0 GB 202306028D0
Authority
GB
United Kingdom
Prior art keywords
prostate cancer
prostate
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GBGB2306028.8A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Swansea University
Original Assignee
University College Cardiff Consultants Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University College Cardiff Consultants Ltd filed Critical University College Cardiff Consultants Ltd
Priority to GBGB2306028.8A priority Critical patent/GB202306028D0/en
Publication of GB202306028D0 publication Critical patent/GB202306028D0/en
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
GBGB2306028.8A 2023-04-25 2023-04-25 Prostate cancer Pending GB202306028D0 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GBGB2306028.8A GB202306028D0 (en) 2023-04-25 2023-04-25 Prostate cancer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2306028.8A GB202306028D0 (en) 2023-04-25 2023-04-25 Prostate cancer

Publications (1)

Publication Number Publication Date
GB202306028D0 true GB202306028D0 (en) 2023-06-07

Family

ID=86605591

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2306028.8A Pending GB202306028D0 (en) 2023-04-25 2023-04-25 Prostate cancer

Country Status (1)

Country Link
GB (1) GB202306028D0 (en)

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
LAMPARSKI HGMETHA-DAMANI AYAO JYPATEL SHSU DHRUEGG C ET AL.: "Production and characterization of clinical grade exosomes derived from dendritic cells", J IMMUNOL METHODS, vol. 270, no. 2, 2002, pages 211 - 26, XP004387999
MELO SALUECKE LBKAHLERT CFERNANDEZ AFGAMMON STKAYE J ET AL.: "Glypican-1 identifies cancer exosomes and detects early pancreatic cancer", NATURE, vol. 523, no. 7559, 2015, pages 177 - 82, XP055845543, DOI: 10.1038/nature14581
MITCHELL JPCOURT JMASON MDTABI ZCLAYTON A: "Increased exosome production from tumour cell cultures using the Integra CELLine Culture System", J IMMUNOL METHODS, vol. 335, no. 1-2, 2008, pages 98 - 105, XP022659940, DOI: 10.1016/j.jim.2008.03.001
OKOLICSANYI RKVAN WIJNEN AJCOOL SMSTEIN GSGRIFFITHS LRHAUPT LM: "Heparan sulfate proteoglycans and human breast cancer epithelial cell tumorigenicity", JOURNAL OF CELLULAR BIOCHEMISTRY, vol. 115, no. 5, 2014, pages 967 - 76, XP055466633, DOI: 10.1002/jcb.24746
THERY CAMIGORENA SRAPOSO GCLAYTON A: "Curr Protoc Cell Biol", 2006, article "Isolation and characterization of exosomes from cell culture supernatants and biological fluids"
VICENTE CMDA SILVA DASARTORIO PVSILVA TDSAAD SSNADER HB ET AL.: "Heparan Sulfate Proteoglycans in Human Colorectal Cancer", ANALYTICAL CELLULAR PATHOLOGY (AMSTERDAM, vol. 2018, 2018, pages 8389595
VICENTE CMLIMA MANADER HBTOMA L: "SULF2 overexpression positively regulates tumorigenicity of human prostate cancer cells", JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH : CR, vol. 34, 2015, pages 25, XP021218357, DOI: 10.1186/s13046-015-0141-x
WELTON JLWEBBER JPBOTOS LAJONES MCLAYTON A: "Ready-made chromatography columns for extracellular vesicle isolation from plasma", JOURNAL OF EXTRACELLULAR VESICLES, vol. 4, 2015, pages 27269

Similar Documents

Publication Publication Date Title
ZA202106392B (en) Therapeutic rna for prostate cancer
GB201905780D0 (en) Cancer therapy
GB202301902D0 (en) Combination therapy for cancer
GB2595425B (en) Prostate cancer biomarkers
GB202306028D0 (en) Prostate cancer
GB202103080D0 (en) Cancer biomarkers
GB202206367D0 (en) Prostate cancer markers
GB202315205D0 (en) Biomarkers for prostate cancer
GB202000739D0 (en) Cancer
GB202318158D0 (en) Cancer therapy
GB202302018D0 (en) Cancer therapy
GB202218395D0 (en) Cancer therapy
GB202212918D0 (en) Cancer therapy
GB202108237D0 (en) Cancer methods
IL304436A (en) Cancer therapy
GB202115337D0 (en) Cancer microenvironment
GB202001963D0 (en) Cancer therapy
GB202000984D0 (en) Cancer therapy
GB202404476D0 (en) Cancer
GB202111635D0 (en) Risk prediction model for prostate cancer
GB202020493D0 (en) Cancer biomarkers
GB202013476D0 (en) Cancer biomarkers
GB202108828D0 (en) Novel cancer therapy
GB202309496D0 (en) Cancer therapies
GB202208893D0 (en) Combination therapy for cancer

Legal Events

Date Code Title Description
COOA Change in applicant's name or ownership of the application

Owner name: SWANSEA UNIVERSITY

Free format text: FORMER OWNER: UNIVERSITY COLLEGE CARDIFF CONSULTANTS LTD